Change of Adviser

14 Nov 2005 07:01

Akers Biosciences, Inc.14 November 2005 AKERS BIOSCIENCES, INC. CHANGE OF ADVISER AND BROKER Following completion of the acquisition of the UK Equity Capital Marketsdivision of Robert W Baird Limited by Bridgewell Securities Limited, AkersBiosciences, Inc. is pleased to announce the appointment of BridgewellSecurities Limited as Nominated Adviser and Broker with immediate effect. For further information please contact: Akers Biosciences, Inc.Dr. Ray Akers, Chief Executive Officer 020 7917 9476 Bridgewell Securities Limited 020 7003 3000Shaun Dobson, Managing Director This information is provided by RNS The company news service from the London Stock Exchange